PROPHASE LABS INC. DL-001

For the quarter ended March 31, 2026, ProPhase Labs reported earnings per share (EPS) of -$0.43 versus $1.10 in the year-ago quarter. Revenue fell 66.43% to $0.5 million from $1.4 million a year earlier. The figures were announced on June 30, 2026, and point to a marked operational deterioration. » More on finanzen.net

ProPhase Labs retained a newly appointed law firm and filed a new legal opinion with the SEC that replaces the opinion previously submitted on October 15, 2025. The company also confirmed a non-binding letter of intent for a reverse merger with Advanced Biological Laboratories S.A., under which ABL would likely hold about 76% of the combined company and value ProPhase’s business at up to $30 million. At the extraordinary general meeting, all proposals were approved, including initiatives on digital assets and an authorization for a stock split; the company also reported a dismissed false-claims action and an updated payment agreement with Avtech Capital. » More on de.investing.com

ProPhase Labs announced a non-binding letter of intent for a reverse merger with Advanced Biological Laboratories (ABL), after which the stock jumped about 75% in pre-market trading. Under the proposed framework, ABL would hold roughly 76% of the shares; ProPhase’s continuing business is preliminarily valued at up to about USD 30 million. As part of the agreement, a special dividend of up to USD 10 million and the spin-off of Crown Medical Collections’ receivables—with expected net proceeds of around USD 50 million for existing shareholders—are envisaged; the combined company would assume about USD 5 million of existing debt. The parties aim to reach a definitive agreement within 60–90 days; the transaction is subject to due diligence, regulatory approvals and NASDAQ listing requirements. » More on de.investing.com